Monte Rosa Therapeutics, Inc. (GLUE)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Monte Rosa Therapeutics, Inc. reported revenue of $123.67M, up 63.5% from the prior year. The company ran a net loss, with a net margin of -31.2%. It held $448.66M in total assets against $215.60M in total liabilities.
Key ratios (FY2025)
-43.8%
Operating margin
-31.2%
Net margin
-16.6%
Return on equity
+63.5%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | $123.67M | $75.62M | $0 | — | — | — |
| Operating Income | -$54.21M | -$81.11M | -$143.31M | -$112.38M | -$72.88M | -$28.01M |
| Net Income | -$38.63M | -$72.70M | -$135.35M | -$108.50M | -$73.96M | -$35.88M |
| Total Assets | $448.66M | $438.73M | $303.75M | $342.39M | $366.33M | $49.38M |
| Total Liabilities | $215.60M | $215.80M | $124.50M | $70.98M | $18.81M | $30.34M |
| Shareholders' Equity | $233.06M | $222.94M | $179.25M | $271.41M | $347.51M | -$48.73M |
| Cash & Equivalents | $129.88M | $224.25M | $128.10M | $54.91M | $346.07M | $41.70M |
| Operating Cash Flow | -$22.80M | $42.00M | -$43.80M | -$92.47M | -$59.36M | -$23.05M |
| Capital Expenditures | $4.70M | $3.99M | $19.04M | $12.91M | $9.73M | $3.39M |
| Shares Outstanding | 65.54M | 61.51M | 50.14M | 49.32M | 46.54M | 1.69M |